Last reviewed · How we verify

Biotinylated Red Blood Cells

John A Widness · Phase 2 active Small molecule

Biotinylated Red Blood Cells is a Small molecule drug developed by John A Widness. It is currently in Phase 2 development. Also known as: BioRBC.

At a glance

Generic nameBiotinylated Red Blood Cells
Also known asBioRBC
SponsorJohn A Widness
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Biotinylated Red Blood Cells

What is Biotinylated Red Blood Cells?

Biotinylated Red Blood Cells is a Small molecule drug developed by John A Widness.

Who makes Biotinylated Red Blood Cells?

Biotinylated Red Blood Cells is developed by John A Widness (see full John A Widness pipeline at /company/john-a-widness).

Is Biotinylated Red Blood Cells also known as anything else?

Biotinylated Red Blood Cells is also known as BioRBC.

What development phase is Biotinylated Red Blood Cells in?

Biotinylated Red Blood Cells is in Phase 2.

Related